Staff

Articles

FDA Grants CLR 131 Fast Track Status for 2 Rare Blood Cancers

May 28, 2020

The FDA has granted a Fast Track designation to CLR 131 for use as a treatment for patients with lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM) who have received at least 2 prior treatment regimens.